Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium

Diagnostic Microbiology and Infectious Disease

Volumn 25, Issue 3, 1996, Pages 127-131

  Bonilla, Hector F ^b   Perri, Mary B ^a   Kauffman, Carol A ^b   Zervos, Marcus J ^a,c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Beaumont Hospital System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DALFOPRISTIN; GENTAMICIN; IMIPENEM; NOVOBIOCIN; QUINUPRISTIN; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030200083     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(96)00123-X     Document Type: Article

References (44)

1. Arthur M, Courvalin P (1993) Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37:1563-1571.
2. Aumercier M, Bouhallab S, Campau ML, Le Goffic F (1992) RP59500: A proposed mechanism for its bactericidal activity. J Antimicrob Chemother 30 Suppl:A9-A14.
3. Barry AL, Fuchs PC (1995) In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 39:238-240.
4. Bonilla HF, Thal L, Donabedian S, Lyons M, Zarins L, Zervos M, Kauffman C (1995) Epidemiology of vancomycin resistant enterococci colonization in a VA Medical Center. J Invest Med 43:485A.
5. Bouanchaud DH (1992) In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 39(Suppl A):95-99.
6. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, Painter BG (1993) Epidemiologic analysis and genotypic charcterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 31:1280-1285.
7. Brumfitt W, Hamilton-Miller, Shah S (1992) In vitro activity of RP59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J Antimicrob Chemother 30 Suppl:A29-A37.
8. Chow JW, Kuritza A, Shlaes DM, Green M, Sahm DF, Zervos MJ. (1993) Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol 31:1609-1611.
9. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC (1993) In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37:598-601.
10. Facklam RR and Collins MD (1989) Identification of enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 27:735-737.
11. Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Quintiliani R, Nightingale C (1995) In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 21:47-50.
12. Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, Eisner W, Warren S, Kreiswirth B (1993) Emergence of vancomycin-resistant enterococci in New York City. Lancet 342:76-79.
13. French P, Venuti E, Fraimow HS (1993) In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicrob Agents Chemother 37:2736-2739.
14. Goldmann DA (1992) Vancomycin-resistant Enterococcus faecium: Headline news. Infect Control Hosp Epidemiol 13: 695-699.
15. Green M, Barbadora K, Michaels M (1991) Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol 29:2503-2506.
16. Guiot HFL, Peetermans WE, Sehens FW (1991) Isolation of vancomycin-resistant enterococci in haematologic patients. Eur J Clin Microbiol Infect Dis 10:32-34.
17. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, Murray BE, Wolff J, Walters B (1993) Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect dis 16:750-755.
18. Hardalo C, Rigsby M, Chen L, Dykewicz C, Elmore J, Nagy-Agren E, Wetherill P, Edberg S, Hierholzer W (1993) Chloramphenicol treatment of resistant Enterococcus faecium infections. 31st Annual Infectious Diseases Society of America. Abstr #110, page 20A.
19. Johnson CC, Slavoski L, Schwartz M, May P, Pitsakis PG, Shur AL, Levison ME (1995) In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 21:169-173.
20. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, Swenson JM (1992) A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 13:195-200.
21. Knapp C, Moody JA (1992) Tests to assess bactericidal activity. In: Clinical Microbiology Procedures Handbook. HC Isenberg (ed). Washington DC: American Society for Microbiology 5.16.1-6.16.32
22. Linden P, Pasculle AW, Riddler S, Kusne S, Silverman A, Dean J (1994) Quinupristin/dalfopristin (RP 59500) for the treatment of serious infection due to high level vancomycin resistant Enterococcus faecium. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstr. #M68.
23. Low DE (1995) Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience. Microbial Drug Resis 1:223-234.
24. Lynn WA, Klutterbuch E, Want S, Markides V, Lazy S, Rogers TR, Cohen J (1994) Treatment of CAPD-peritonitis due to glyopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 334:1025-1026.
25. Moellering RC, Wennersten C, Weinberg AN (1971) Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med 77:821-828.
26. Moellering RC (1995). Past, present, and future of antimicrobial agents. Am J Med 99 (Suppl 6A):11S-18S.
27. Moellering RC (1992) Emergence of enterococcus as a significant pathogen. Clin Infect Dis 14:1173-1178.
28. Montecalvo MA, Horowitz H, Wormser GP (1995) Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 39:794.
29. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP (1994) Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 38:1363-1367.
30. Moreno F, Jorgensen JH, Weiner MH (1994) An old antibiotic for a new multiple-resistant Enterococcus faecium. Diagn Microbiol Infect Dis 20:41-43.
31. Murray BE (1990) The life and times of the enterococcus. Clin Microbiol Rev 3:46-65.
32. National Committee for Clinical Laboratory Standards (1993) Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
33. Neu HC, Chin NX, Gu JW (1992) The in-vitro activity of new streptogramins, RP59500, RP57609, and RP54476 alone and in combination. J Antimicrob Chemother 30 Suppl:A83-A94.
34. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG (1995) Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 20:1137-1144.
35. Quale JM, Landman D, Mobarakai N (1994) Treatment of experimental endocraditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin. J Antimicrob Chemother 34:797-802.
36. Rice LB, Carias LL (1994) RP59500 (quinupristin/ dalfopristin) in combination with other antimicrobials against multiply-resistant E. faecalis and E. faecium. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst #E90.
37. Ristow TA, Noskin GA, Warren JR, Peterson LR (1995) In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microbial Drug Resis 1:335-339.
38. Sader HS, Pfaller MA, Tenover FC, Hollis RJ, Jones RN (1994) Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J Clin Microbiol 32:2840-2842.
39. Schaberg DR, Culver DH, Gaynes RP (1991) Major trends in the microbial etiology of nosocomial infections. Am J Med 91(Suppl 3B):72S-75S.
40. Shlaes DM, Al-Obeid S, Shlaes JH, Boisivon A, Williamson R (1989) Inducible, transferable resistance to vancomycin in Enterococcus faecalis. J Antimicrobial Chemother 23: 503-508.
41. Torralba MD, Frey SE, Lagging LM (1995) Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin. Clin Infect Dis 21:460-461.
42. Tucker L, Peterson L, Noskin G, Cooper I, Reisberg B (1993) Activity of 32 antimicrobial agents alone and in combinations against high level vancomycin-resistant Enterococcus faecium. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstr #1061.
43. Weiss WJ, Jacobus NV, Petersen PJ, Testa RT (1995) Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoninae to the glycylcyclines. J Antimicrob Chemother 36:225-230.
44. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesel TS, Schaberg DS (1987) Nosocomial infection by gentamicin-resistant Streptococcus faecalis: An epidemiologic study. Ann Intern Med 106:687-691.